Molecular data
| Physical form | Lyophilized powder blend |
|---|---|
| Available sizes | 10mg / 10mg |
How it works
-
BPC-157
Preclinical Remodelling
BPC-157 copies part of a protein found in gastric fluid. Preclinical models have measured new blood vessel growth, tendon cell migration and tissue remodelling after injury.
- Angiogenesis endpoints
- Tendon cell migration
- Stable in acidic conditions
-
KPV
NF-kB Signalling
KPV is the C-terminal tripeptide of alpha-MSH. It carries the anti-inflammatory portion of that sequence without the pigmentation-associated portion, and NF-kB pathway endpoints are the characterised readouts.
- alpha-MSH 11-13 fragment
- NF-kB pathway endpoints
- Small size, high stability
-
Combined
Two Signalling Angles
The vial pairs a long synthetic peptide with a three amino acid fragment. The two are characterised separately and no interaction data exists for the pair.
- Remodelling and signalling arms
- Matched handling
- Interaction not characterised
What the research shows
-
Cell Biology
Inflammatory Signalling
KPV is characterised for NF-kB pathway endpoints in cell models.
-
Cell Biology
Angiogenesis Models
BPC-157 has been measured for new blood vessel growth in preclinical models.
-
Cell Biology
Tissue Remodelling
Both peptides appear in tissue-remodelling literature from different angles.
-
Methods
Parallel Protocols
One vial holds both peptides under matched handling.
Specification
| Components | BPC-157 + KPV |
|---|---|
| Content | 20 mg per vial (10 mg of each component) |
| BPC-157 | Synthetic pentadecapeptide, CAS 137525-51-0 |
| KPV | Lys-Pro-Val (α-MSH 11-13) |
| Form | Lyophilized powder blend |
| Purity | ≥99% by HPLC |
| Appearance | White to off-white powder |
| Solubility | Water-soluble |
| Storage | -20°C, protected from light |
| Classification | Research use only |
Frequently asked questions
Why combine BPC-157 and KPV?
They approach inflammatory and tissue research from different angles: BPC-157 through angiogenesis and remodelling endpoints in preclinical models, KPV through NF-kB pathway endpoints. One vial holds both under matched handling.
How is this different from the TB-500 / KPV / BPC-157 blend?
That is a separate three-peptide product that also contains TB-500 and is supplied at a different ratio. This vial holds only BPC-157 and KPV, 10 mg of each.
Has the combination been characterised as a single formulation?
No. Each peptide is characterised separately and no interaction data exists for the pair.
How does this differ from buying BPC-157 and KPV separately?
The separate products let you control each peptide quantity independently and are offered in more than one size. This vial fixes the ratio at 10 mg and 10 mg.
What purity is documented?
Each lot is analysed by reverse-phase HPLC and released at ≥99%, with a Certificate of Analysis.
How is it stored?
Store lyophilized at -20°C for long-term stability, protected from light and moisture, and avoid repeated freeze-thaw cycles.
Related monographs
For laboratory research use only. Not a drug, supplement, or medical product; not for human or animal use. All findings referenced are from published preclinical/laboratory research.